To present an overview of the company

Sucampo Pharma Asia announced earnings results for third quarter and nine months ended Sept. 30, 2009. For the quarter the company reported loss from operations of $382,000, interest income of $2,000, loss before income taxes of $659,000 on revenues of $3,765,000 compared to loss from operations of $890,000, interest income of $2,000, loss before income taxes of $909,000 on revenues of $213,000, for the same period a year ago. For the nine months, the company reported loss from operations of $3,453,000, interest income of $4,000, loss before income taxes of $3,474,000 on revenues of $8,144,000 compared to loss from operations of $3,914,000, interest income of $5,000, loss before income taxes of $3,929,000 on revenues of $630,000 for the same period a year ago. The company reported capital expenditures of $116,000 compared to capital expenditures $3,000, for the same period a year ago.

Sucampo Pharmaceuticals Inc. announced unaudited consolidated earnings results for third quarter and nine months ended Sept. 30, 2009. For the quarter, the company reported income from operations of $1,420,000, income before income taxes of $1,381,000, net loss of $88,000 on revenues of 17,831,000 compared to loss from operations of $4,811,000, loss before income taxes of $4,171,000, net loss of $2,426,000 or $0.06 per diluted share on revenues of $14,481,000, for the same period a year ago. Capital expenditures were $151,000 against $40,000 for the same period a year ago. For the nine months, the company reported loss from operations of $74,000, income before income taxes of $632,000, net loss of $2,101,000 or $0.05 per diluted share on revenues of $51,050,000 compared to income from operations of $33,301,000, interest income of $1,862,000, income before income taxes of $35,147,000, net income of $27,955,000 or $0.67 per diluted share on revenues of $95,749,000, for the same period a year ago. Capital expenditures were $3,378,000 against $342,000 for the same period a year ago.